This morning femtech company kegg announced a $3 million seed funding round for its cervical fluid testing and pelvic floor exercise technology. Crescent Ridge Partners led the round with SOSV, Texas Halo Fund, Althea Capital Fund, Ad Astra Ventures, Viento Ventures and other angel investors. 

This news comes just a year after the company scored $1.5 million, bringing its total raise to $4.5 million. 

WHAT IT DOES 

The company is focused on helping individuals understand their fertility window by analyzing a user’s cervical fluids. The system includes a small egg-shaped device with a “tail” called a kegg and a corresponding smartphone app. In order to conduct a cervical fluid assessment, users are instructed to insert the kegg into their vagina with the tail hanging out. The kegg will give users a vibration when the reading begins and two vibrations when the reading has completed. The test takes about two minutes. 

After the reading is complete, users will get their results on their smartphone app. Users can access insights about their cycle on a graph and record additional notes about their sexual activity and LH test. Users are instructed to take the test once a day within the same two-hour window throughout their cycle, except during their period or within eight hours of intercourse. 

The company says that the device is also able to function as a kegel ball for pelvic floor exercises and help women keep track of their cycles. 

WHAT IT’S FOR 

The company plans to use the new cash to build out its services to the perimenopause, menopause, postpartum and infections spaces. Additionally, the company plans to use the money to expand its research collaborations and pilots. 

MARKET SNAPSHOT 

Fertility tech is on the rise in the digital health world. In March, Proov, an at-home ovulation test kit, landed FDA clearance.  U.K.-based Concepta Diagnostics rolled out the myLotus Fertility app and monitoring system in 2018, which lets women trying to conceive test their hormone levels at home. Additionally Mira created an FDA cleared at-home fertility testing system. 

According to a Frost & Sullivan study Femtech is expected to reach a $1.15 billion market by 2025. While femtech is catching more investor attention, it still has a long way to go. A  Rock Health report found that femtech only accounts for 3% of digital health funding deals in the U.S. since 2011.